Skip to content

Depression research published in 2026

Page 16 of 37: studies 301 to 320 of 728, newest first. Back to the depression overview

Studies

Unmasking the psychiatric impact of ketamine in burn patients: Elevated risk of depression and acute stress reactions

Journal of Surgery and Medicine June 11, 2026 Davon Lee, Elizabeth Beyene, Da’Jhai Monroe et al.

Background/Aim: Ketamine is frequently administered for analgesia and sedation during burn dressing changes, but its potential psychological impact remains a concern. This study assessed whether ketamine exposure during early burn care is associated with subsequent depression, acute stress reaction (ASR), or post-traumatic stress disorder (PTSD) in patients with major burns. Methods: A...

Telehealth-supported ketamine for depression and anxiety: A systematic review.

Australasian Psychiatry June 11, 2026 Eden Mane, Saras Mane

ObjectivesTo systematically review the effectiveness, safety, and care models of telehealth-supported ketamine for depression and/or anxiety in adults and consider implications for Australasian clinical practice.MethodsFollowing PRISMA 2020, we searched for randomised or observational studies of adults receiving at-home telehealth-supported ketamine for depression and/or anxiety, to August...

Functional outcomes with esketamine in treatment-resistant depression: A 6-month multicenter real-world study.

European Psychiatry June 10, 2026 Riccardo Guglielmo, Miriam Olivola, Alberto Inuggi et al.

Esketamine has demonstrated efficacy in treatment-resistant depression (TRD), but medium-term real-world functional outcomes remain understudied. This study described 6-month depressive symptoms and functional trajectories during routine esketamine treatment, focusing on functional outcomes and remission correlates. In this prospective multicenter study, 60 patients with TRD initiating...

Ketamine-Assisted Psychotherapy for Depression: A Survey of Current Practices, Rationales, and Future Directions.

Journal of Psychoactive Drugs June 10, 2026 Jack H Buchanan, Brandon Reynante, Michael T. Dinh et al.

Ketamine-assisted psychotherapy (KAP) is an emerging treatment approach that may enhance ketamine's antidepressant effects through neuroplastic synergism or transformative psychological experience. Despite growing clinical use, real-world KAP practices remain understudied. This cross-sectional survey examined the practices of fifty licensed KAP providers treating depression, recruited from a...

Aquahenosis: A non-pharmacological altered state of consciousness induced by Floatation-REST in individuals with anxiety and depression

PsyArXiv June 10, 2026 Theo Tobel, Aidan Cone, Emily Choquette et al. preprint

Floatation-REST (Reduced Environmental Stimulation Therapy) systematically alters sensory and bodily input by combining neutral buoyancy, thermal and proprioceptive neutrality, attenuation of exteroceptive stimulation, and enhancement of cardiorespiratory signaling to the brain. Here we examined whether this non-pharmacological sensory perturbation induces altered states of consciousness and...

DOI: 10.31234/osf.io/6mj8n_v2 (opens in new tab) Altered state Perception Arousal Cardiorespiratory fitness +11

[Intravenous Subnarcotic Ketamine Infusions for Treatment-Resistant Depression: Historical Development, Comparison with Esketamine Nasalspray, and Prospects].

Fortschritte der Neurologie · Psychiatrie June 8, 2026 Udo Bonnet, Norbert Scherbaum, Georg Juckel et al.

Introduction: Esketamine nasal spray (EN) has been approved in Germany since 2021 for the treatment of treatment-resistant depression (TRD). Historically, the development of EN resulted from the positive results of randomized clinical trials on the off-label use of subnarcotic ketamine infusions (SKI) for TRD. How effective, tolerable, and safe is off-label SKI compared to EN? Methods: Narrativ...

Prescribing bias and adverse outcomes of esketamine in major depression comorbid substance.

Journal of Affective Disorders June 8, 2026 Dian‐jeng Li, Tien-Wei Hsu, Te-Chang Changchien et al.

Little is known about esketamine's effectiveness for patients with major depressive disorder (MDD) comorbid substance use disorders (SUD). We conducted a retrospective cohort study using the TriNetX US Collaborative Network, including adults aged ≥18 years with MDD. Three propensity-score-matched (1:1) cohorts were defined based on treatment: esketamine, antidepressant-only, and repetitive...

Comparing transcranial magnetic stimulation and esketamine treatment response trajectories in resistant depression.

Journal of Affective Disorders June 7, 2026 Lindsay L Benster, Jordan N Kohn, Benjamin Wade et al.

Repetitive transcranial magnetic stimulation (rTMS) and intranasal esketamine are FDA-approved for treatment-resistant depression (TRD), yet comparative real-world data on response trajectories and predictors of outcomes remain limited. A retrospective analysis was performed using electronic medical records from UC San Diego Health. Adults with TRD treated with rTMS (n = 279) or intranasal...

Effect of a digital mindfulness intervention for mild-to-moderate late-life depression: A randomized controlled trial.

Journal of Psychiatric Research June 6, 2026 Kemeng Zhu, Maoxin Hu, Chaomeng Liu et al.

Background: Late-life depression (LLD) is a growing public health concern in aging populations. Although digital mindfulness interventions show promise for depression, anxiety, and insomnia, their efficacy and electroencephalogram (EEG) correlates in older adults with LLD remain unclear. This study evaluated the FocusZen Mindfulness Stress Reduction System, a digital mindfulness intervention...

Electroconvulsive Therapy and Ketamine Infusion in Patients with Bipolar I or II Depression: A Case Series.

Psychopharmacology Bulletin June 5, 2026 Keming Gao, Evrim Bayrak Oruc, Heather Wobbe et al.

To compare the efficacy and safety of electroconvulsive therapy (ECT) and ketamine infusion (KET-IFU) in routine care for patients with bipolar I or II depression (BPD). Electronic medical records of patients who received ECT and/or KET-IFU were used to identify patients with BPD who received both ECT and KET-IFU treatments. The change in the 16-item Quick Inventory of Depressive Symptomatology...

GH001 Efficacy is Independent of Prior Antidepressant Treatment Failures in Treatment-Resistant Depression: A Post Hoc Analysis of a Phase 2b Randomized Controlled Trial.

Psychopharmacology Bulletin June 5, 2026 Michael E. Thase, Brian Brennan, Rachael Macisaac et al.

Approximately 30% of patients treated for major depressive disorder develop treatment-resistant depression (TRD). The STAR*D study demonstrated remission rates decline progressively with each antidepressant failure (37%, 31%, 14%, and 13%, respectively). A single-day individualized dosing regimen of GH001 (synthetic mebufotenin for inhalation) produced rapid, large improvements in depressive...

Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression.

Journal of Affective Disorders June 4, 2026 Carlton M Kelly, Mathieu Fradet, Catherine Bostian et al.

Psilocybin has demonstrated promise for improving depressive symptoms in treatment-resistant depression, but its effects on anxiety, quality of life, functioning, and posttraumatic stress symptoms are less well studied. This study reports exploratory findings from an open-label trial in Veterans with TRD. Participants received a single 25-mg dose of psilocybin administered with psychological...

Positive Affect as a Transdiagnostic Target for Reducing Adolescent Depression & Suicide Risk: Do Mindfulness, Savoring, & Gratitude Help?

Journal des adolescens June 3, 2026 Natalia Macrynikola, Jackson Doerr, Shirley Yen

INTRODUCTION Despite its known contribution to adolescent depression and suicide risk, low positive affect (PA) remains underemphasized in clinical interventions, with limited evidence on how to best enhance it. Using data from a pilot randomized controlled trial of a brief PA-enhancing intervention for high-risk youth, we hypothesized that increases in PA over the intervention period would...

Novel 5,6-Bicyclic Compounds as 5-HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches

ACS Medicinal Chemistry Letters June 3, 2026 Ram W. Sabnis, Anika R. Sabnis

Provided herein are novel 5,6-bicyclic compounds as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating depression, anxiety, substance abuse and headaches, and processes for preparing such compounds.

Inhaled Mebufotenin (GH001) for Adult Patients With Postpartum Depression: A Phase 2a Open-Label Clinical Trial.

The Journal of Clinical Psychiatry June 3, 2026 Martin Johnson, Pau Aceves Baldo, Emilio Arbe et al.

Objective: Postpartum depression (PPD) is a debilitating mood disorder with peripartum onset. Current treatment options are limited in PPD. GH001 is a synthetic inhalation formulation of the psychoactive molecule mebufotenin (5-MeO-DMT). This trial investigated the preliminary efficacy and safety of GH001 in adult females with PPD. Methods: This phase 2a, proof-of-concept, open-label trial...

The Correlation between Islamic Mindfulness with Anxiety, Stress and Depression Among Women in the Menopausal period

Media Keperawatan Indonesia June 2, 2026 Siti Sarah Azzahra, Irma Nurbaeti, Puspita Palupi et al.

Menopause is a natural phase in a woman's life marked by the cessation of ovarian function and hormonal changes in estrogen and progesterone, often accompanied by physical and psychological symptoms such as anxiety, stress, and depression. One possible way to deal with these changes is to practice mindfulness, especially Islamic mindfulness, which is in line with Islamic values. This study aims...

Effects of alpha-pinene on depressive behaviors in a dextromethorphan-induced depression model in rats.

Journal of Taibah University Medical Sciences June 2, 2026 Danial Hasanisadr, Kaveh Rahimi, Zohreh Ghotbeddin

Background: Depression, a multifactorial psychiatric disorder, affects millions of people worldwide and has limited effective therapeutic options. This study was aimed at investigating the potential antidepressant effects of alpha-pinene (aPI) in a dextromethorphan (DEX)-induced pharmacological model in rats. Methods: Thirty-two adult male Wistar rats were randomly assigned to four groups (n =...

DOI: 10.1016/j.jtumed.2026.05.007 (opens in new tab) Full text (opens in new tab) Rats Alpha-pinene Dextromethorphan Depressive behaviors

[Expérience d'une introduction à la pleine conscience chez des personnes vieillissantes à risque de déclin cognitif].

Canadian Journal on Aging June 2, 2026 Andréanne Simard, Isabelle F-Dufour, Sonia Goulet et al.

Les interventions basées sur la pleine conscience (IBPC) sont reconnues comme des approches pertinentes auprès de personnes vieillissantes à risque de déclin cognitif. Toutefois, peu d'études ont exploré l'expérience vécue de participants présentant un déclin cognitif accompagné de symptômes anxiodépressifs. Cette étude qualitative vise à comprendre l'expérience de 13 adultes de 55 ans et plus...

Patient reported outcomes of MDD patients treated with esketamine nasal spray in real world practice: the French ELLIPSE study

European Psychiatry June 1, 2026 P.-M. Llorca, Ludovic Samalin, Emilie Olié et al.

Introduction: Esketamine nasal spray (ESK) was approved in 2019 in Europe for adults with Treatment-Resistant Depression (TRD), defined as inadequate response to at least two different antidepressants during the current moderate to severe depressive episode Objectives: To assess patient-reported outcomes related to symptomatology, quality of life, and occupational impairment over 12 months...